<b>Objective:</b> Previous studies have reported that Ile462Val polymorphism in the gene Cytochrome P450 1A1 (<i>CYP1A1</i>) is associated with the risk of cervical cancer, but inconsistent results have emerged.
(2) rs1048943 (CYP1A1A4889G) showed the strongest association with cervical cancer in the allele effect model (1.83[1.57, 2.13]); in addition, rs1048943 (CYP1A1A4889G) had a very strong association in the dominant and recessive effect model.
An association with cervical cancer and high-grade dysplasia was found for the rare homozygous CC genotype (rs4646903) in CYP1A1 (odds ratio [OR], 8.862).
Meta-analysis of the ten studies on cervical cancer suggested a significant association between the CYP1A1T3801C polymorphism and cervical cancer risk (C vs. T, OR 1.38, 95 % CI 1.05-1.82, P = 0.02; CC vs. TT, OR 2.06, 95 % CI 1.15-3.70, P = 0.02; CC/CT vs. TT, OR 1.45, 95 % CI 1.03-2.02, P = 0.03; CC vs. TT/CT, OR 1.56, 95 % CI 1.20-2.03, P < 0.01).
Our genetic study suggests that the CYP1A1Ile462Val SNP may be a risk factor for cervical cancer among patients with a positive history of tobacco smoking and parity.
The CYP1A1 gene involved in the metabolic pathway of sex steroids might influence the emergence of pathological conditions such as cervical cancer in women who carry a mutated allele, and result in 1.80 and 13.46 times increased risk for women with heterozygous or homozygous mutated genotypes, respectively.
The purpose of this study was to evaluate the role of CYP1A1*3 gene polymorphism in the development of cervical cancer by comparing patients having cervical intraepithelial neoplasia (CIN) or invasive cervical cancer with control subjects.